clinical trial · NCT05878860
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
X-linked RetinoschisisATSN-201
brief summary
This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).
started
Aug 22, 2023
primary completion
Oct 1, 2025
completion
Oct 1, 2029
last updated
Feb 19, 2025
detailed description
Eligible patients who enroll in this study will receive a one-time subretinal injection of ATSN-201 in one eye. Safety and tolerability will be evaluated for 5 years.
official title
A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Tolerability of ATSN-201 Gene Therapy in Male Subjects With RS1-Associated X-linked Retinoschisis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol